VFDB - antivirulence drug 2-{3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl}-1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanone

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

2-{3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl}-1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanone

Drug details:
Molecular formula: C₂₅H₃₆N₄O

Standard name: 1-(1-adamantyl)-2-[3-[2-(diethylamino)ethyl]-2-iminobenzimidazol-1-yl]ethanone

Classification: Benzimidazoles; Organoheterocyclic compounds; Organic compounds;

Curated SMILES: CCN(CC)CCN1C2=CC=CC=C2N(C1=N)CC(=O)C34CC5CC(C3)CC(C5)C4

Chemical structure:

Bacillus
Related VFcategory: Nutritional/Metabolic factor
Target: KtrAB
Drug effect: Inhibits KtrAB ion channel complex, a component of the K+ homeostasis machinery to interfere with pathogen survival in host cells.
Max phase: In vitro
Publication:
Fernandes AS, et al., 2021. Fluorometric Liposome Screen for Inhibitors of a Physiologically Important Bacterial Ion Channel. Front Microbiol 12:603700.


	Back to Top

2004-2024 NIPB, CAMS&PUMC